ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is...
4 insider purchases on record · latest filing 2024-02-01.
Insiders have also filed 1 sale transaction at AVBP.